Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.

Mergers & acquisitions

Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking as Top Candidate: Analysts

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered by its strong obesity candidate VK2735 and largely de-risked MASH therapy VK2809.

January 6, 2025

2 min read

Tristan Manalac

Symbol of money dollar from colored pills and capsules on green background. Expensive medicine and medical insurance

Venture Capitalists

Novo-Backed Oral Medicine Biotech Adds Lilly to Investors in $93M Series A

Orbis emerged from stealth in February 2024 with $28.1 million in seed funding. The Danish biotech, which aims to flip biologics into oral medicines, has now raised another $93 million.

January 6, 2025

1 min read

Annalee Armstrong

FDA signage at its headquarters in Maryland

Regulatory

5 FDA Decisions to Watch in Q1

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy for hemophilia A and B.

January 6, 2025

8 min read

Tristan Manalac

GLP-1

Evidence Mounts for Benefit of GLP-1s Against Heart Disease

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular benefits in the world’s fastest-growing drug class.

January 6, 2025

6 min read

Kate Goodwin

Colorful Pills scattered from white plastic pill bottle on blue background.

Opinion

The Cocktail Recipe that Will Cure Alzheimer’s

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of approaches, as well as a drive toward early detection.

January 6, 2025

4 min read

Robert Cupelo

View of traffic on the Bay Bridge with downtown San Francisco and stormy sky in background

Mergers & acquisitions

Biopharma Heads to JP Morgan Seeking an M&A Spark to Improve Sentiment

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.

January 6, 2025

5 min read

Annalee Armstrong

Opinion

Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 Products?

Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how.

January 3, 2025

6 min read

Gary Stibel

Eli Lilly's world headquarters in Indianapolis

GLP-1

Lilly Asks to Join GLP-1 Compounding Lawsuit

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.

January 3, 2025

2 min read

Nick Paul Taylor